Want to see NERV full AI Analyst Report?
NERV Stock Chart & Stats
$4.04
$0.20(4.95%)
At close: 4:00 PM EDT
$4.04
$0.20(4.95%)
Day’s Range― - ―
52-Week Range$1.87 - $12.46
Previous CloseN/A
Volume117.94K
Average Volume (3M)465.60K
Market Cap
$187.17M
Enterprise Value$435.40
Total Cash (Recent Filing)$75.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.37
Shares Outstanding47,747,560
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside110.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Governance Strengthening And ContinuityBoard-approved charter and bylaw amendments, director elections, and ratified auditor clarify legal framework and shareholder mechanics. Stronger governance and continuity reduce procedural risk, improve investor engagement, and support steady oversight—beneficial for executing long multi-year clinical programs.
Established ATM Financing CapacityAn at-the-market facility formalizes a flexible capital-raising pathway to fund operations and trials, lowering the immediacy of a single large financing. This structural access to equity markets supports trial continuity and reduces execution risk for multi-year development plans, albeit with potential dilution.
Advanced Phase 3 CNS Pipeline With Defined MilestonesA pivotal Phase 3 program with explicit timelines and extended relapse assessment represents a tangible, high-value clinical asset. Successful pivotal data could materially transform the company from pre-revenue to a revenue-generating biopharma, making the pipeline a durable fundamental growth lever over the next 2–3 years.
Bears Say
No Revenue And Persistent Operating LossesThe company lacks recurring revenue and has sustained operating losses across reported periods, indicating no internal cash generation from products. This structural deficit requires ongoing external funding, heightening refinancing risk and constraining long-term investment flexibility until commercial revenues emerge.
Persistent And Worsening Negative EquityDeepening negative equity reflects accumulated losses that weaken the capital structure and reduce financial flexibility. Over time this can limit borrowing capacity, increase dependence on dilutive equity raises, and complicate strategic partnerships or licensing deals that favor counterparties with stronger balance sheets.
Weak Cash Generation And Accelerating Cash BurnConsistently negative operating and free cash flow, with acceleration in recent periods, indicates the company is consuming capital faster than it generates it. This persistent burn increases likelihood of repeated financings, which can be dilutive and distract management from R&D execution and long-term value creation.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.87 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $187.17M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Aug 07, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.053.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.17.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 47,747,560 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -3.829%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Minerva Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (110.40% Upside)
$8.50 (110.40% Upside)
Blogger Sentiment
Bullish
NERV Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
212.59%
Trailing 12-Months
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
NERV Stock 12 Month Forecast
Average Price Target
$8.50
▲(110.40% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
―
Aspire Biopharma Holdings
―
Ownership Overview
1.00%
Insiders
5.08% Mutual Funds
42.18% Other Institutional Investors
44.99% Public Companies and
Individual Investors